Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Visible Genetics

This article was originally published in The Gray Sheet

Executive Summary

Investment of $30 mil. by private equity investment firm E.M Warburg, Pincus & Co. is outlined in a letter of intent agreement. The maker of high-performance, automated DNA sequencing systems and kits for the analysis of genes linked to disease plans to use the proceeds to continue development and commercialization of its HIV, hepatitis B and C, and tuberculosis GeneKit products as well as for debt repayment. Second-quarter revenues are estimated at $1.9 mil
Advertisement
Advertisement
UsernamePublicRestriction

Register

MT012131

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel